Santhera

Santhera debuts DMD drug Agamree in Germany
Pharmaphorum
Mon, 01/15/24 - 09:37 am
Santhera
Duchenne Muscular Dystrophy
DMD
Agamree
Germany
Santhera closes on first approval for DMD drug vamorolone
Pharmaphorum
Fri, 10/13/23 - 10:23 am
Santhera
Duchenne Muscular Dystrophy
DMD
vamorolone
EMA
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
Thu, 03/16/23 - 09:49 am
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Santhera seeks speedy FDA review of Duchenne drug vamorolone
Pharmaphorum
Fri, 10/28/22 - 10:26 am
Santhera
Duchenne Muscular Dystrophy
vamorolone
FDA
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
Pharmaforum
Tue, 11/23/21 - 09:43 am
Santhera
DMD
Duchenne Muscular Dystrophy
idebenone
vamorolone
FDA
Second-quarter catalysts for the smaller players
EP Vantage
Wed, 04/7/21 - 10:25 am
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Tue, 11/3/20 - 09:29 pm
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Endpoints
Mon, 11/2/20 - 10:23 am
Santhera
reorganization
Duchenne Muscular Dystrophy
vamorolone
layoffs
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Wed, 09/2/20 - 11:04 am
Santhera
vamorolone
Duchenne Muscular Dystrophy
Idorsia
ReveraGen
Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Endpoints
Tue, 08/27/19 - 11:01 pm
Santhera
Duchenne Muscular Dystrophy
clinical trials
vamorolone
RaveraGen
Early access to Santhera’s DMD therapy Raxone extended in the UK
Pharma Times
Fri, 06/22/18 - 10:26 pm
UK
Santhera
Raxone
Duchenne Muscular Dystrophy
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
Mon, 02/27/17 - 09:15 am
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD
Investors.com
Fri, 07/15/16 - 10:15 am
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
Raxone
Kyndrisa
Santhera
Duchenne Drug Developer (Not Sarepta) Hit with Lengthy FDA Delay
TheStreet.com
Thu, 07/14/16 - 09:20 am
Raxone
Duchenne Muscular Dystrophy
Santhera
Santhera May Market Muscular Dystrophy Drug on its Own in U.S.
Bloomberg
Wed, 04/15/15 - 09:01 am
Santhera
Duchenne Muscular Dystrophy
Catena
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
TheStreet.com
Tue, 01/6/15 - 08:52 am
Sanofi
MannKind
Gilead Sciences
Santhera
Puma Biotechnology
Bluebird Bio
Celgene
Pfizer
Biogen Idec
InVivo's Pharma Deals of the Week
InVivo
Fri, 08/28/09 - 12:08 pm
Biovail
Santhera
Warner Chilcott
Proctor & Gamble
Ligand
Neurogen
Shire
Santaris
Biovail to develop Parkinson Drug
Yahoo/Zacks.com
Mon, 08/24/09 - 09:54 pm
Biovail
Parkinson's Disease
Santhera